AKBA
NASDAQ
$1.28
Akebia Therapeutics Inc (AKBA)
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts.
Sector:
Healthcare
Strong Buy
Target: $4.20 (+228.13%)
Market Cap
$370M
Free Cash Flow Yield
16.24%
Beta (5Y)
1.25
Price Chart
Valuation
Market Cap$370M
Forward P/E28.74
P/S1.62
P/B13.62
Profitability
Total Revenue (TTM)$232M
Gross Profit (TTM)$190M
EBITDA$6.57M
Profit Margin-16.9%
Operating Margin-8.8%
EPS-$0.08
Financial Health
Debt-to-Equity178.6%
Free Cash Flow Yield16.24%
Growth & Risk
EPS 5Y CAGR-35.14%
Revenue 5Y CAGR-2.15%
Beta (5Y)1.25
Sharpe Ratio-1.11